journal
MENU ▼
Read by QxMD icon Read
search

Lancet Oncology

journal
https://www.readbyqxmd.com/read/28803795/integrative-sequencing-of-metastatic-cancer
#1
Priya Venkatesan
No abstract text is available yet for this article.
August 10, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28803794/arsenic-trioxide-consolidation-in-apl
#2
Manjulika Das
No abstract text is available yet for this article.
August 10, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28802802/nodal-stage-migration-and-prognosis-in-anal-cancer-a-systematic-review-meta-regression-and-simulation-study
#3
Hema Sekhar, Marcel Zwahlen, Sven Trelle, Lee Malcomson, Rohit Kochhar, Mark P Saunders, Matthew Sperrin, Marcel van Herk, David Sebag-Montefiore, Matthias Egger, Andrew G Renehan
BACKGROUND: In patients with squamous cell carcinoma of the anus (SCCA), lymph node positivity (LNP) indicates poor prognosis for survival and is central to radiotherapy planning. Over the past three decades, LNP proportion has increased, mainly reflecting enhanced detection with newer imaging modalities; a process known as nodal stage migration. If accompanied by constant T stage distributions, prognosis for both lymph node-positive and lymph node-negative groups may improve without any increase in overall survival for individual patients; a paradox termed the Will Rogers phenomenon...
August 9, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28802801/nodal-status-and-survival-in-anal-cancer
#4
Rodrigo Oliva Perez, Guilherme Pagin São Julião, Bruna Borba Vailati
No abstract text is available yet for this article.
August 9, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28800863/targeting-pi3k-akt-pathway-in-triple-negative-breast-cancer
#5
Suzette Delaloge, Louise DeForceville
No abstract text is available yet for this article.
August 8, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28800862/nice-guidance-on-cabozantinib-for-previously-treated-advanced-renal-cell-carcinoma
#6
Ahmed Elsada, Amanda I Adler
No abstract text is available yet for this article.
August 8, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28800861/ipatasertib-plus-paclitaxel-versus-placebo-plus-paclitaxel-as-first-line-therapy-for-metastatic-triple-negative-breast-cancer-lotus-a-multicentre-randomised-double-blind-placebo-controlled-phase-2-trial
#7
Sung-Bae Kim, Rebecca Dent, Seock-Ah Im, Marc Espié, Sibel Blau, Antoinette R Tan, Steven J Isakoff, Mafalda Oliveira, Cristina Saura, Matthew J Wongchenko, Amy V Kapp, Wai Y Chan, Stina M Singel, Daniel J Maslyar, José Baselga
BACKGROUND: The oral AKT inhibitor ipatasertib is being investigated in cancers with a high prevalence of PI3K/AKT pathway activation, including triple-negative breast cancer. The LOTUS trial investigated the addition of ipatasertib to paclitaxel as first-line therapy for triple-negative breast cancer. METHODS: In this randomised, placebo-controlled, double-blind, phase 2 trial, women aged 18 years or older with measurable, inoperable, locally advanced or metastatic triple-negative breast cancer previously untreated with systemic therapy were recruited from 44 hospitals in South Korea, the USA, France, Spain, Taiwan, Singapore, Italy, and Belgium...
August 8, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28800860/correction-to-lancet-oncol-2017-18-e429
#8
(no author information available yet)
No abstract text is available yet for this article.
August 8, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28784312/neoadjuvant-cisplatin-and-fluorouracil-versus-epirubicin-cisplatin-and-capecitabine-followed-by-resection-in-patients-with-oesophageal-adenocarcinoma-uk-mrc-oe05-an-open-label-randomised-phase-3-trial
#9
Derek Alderson, David Cunningham, Matthew Nankivell, Jane M Blazeby, S Michael Griffin, Adrian Crellin, Heike I Grabsch, Rupert Langer, Susan Pritchard, Alicia Okines, Richard Krysztopik, Fareeda Coxon, Joyce Thompson, Stephen Falk, Clare Robb, Sally Stenning, Ruth E Langley
BACKGROUND: Neoadjuvant chemotherapy before surgery improves survival compared with surgery alone for patients with oesophageal cancer. The OE05 trial assessed whether increasing the duration and intensity of neoadjuvant chemotherapy further improved survival compared with the current standard regimen. METHODS: OE05 was an open-label, phase 3, randomised clinical trial. Patients with surgically resectable oesophageal adenocarcinoma classified as stage cT1N1, cT2N1, cT3N0/N1, or cT4N0/N1 were recruited from 72 UK hospitals...
August 4, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28781172/selective-internal-radiotherapy-in-advanced-colorectal-cancer-only-for-right-sided-tumours
#10
Hans-Joachim Schmoll
No abstract text is available yet for this article.
August 3, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28781171/first-line-selective-internal-radiotherapy-plus-chemotherapy-versus-chemotherapy-alone-in-patients-with-liver-metastases-from-colorectal-cancer-foxfire-sirflox-and-foxfire-global-a-combined-analysis-of-three-multicentre-randomised-phase-3-trials
#11
Harpreet S Wasan, Peter Gibbs, Navesh K Sharma, Julien Taieb, Volker Heinemann, Jens Ricke, Marc Peeters, Michael Findlay, Andrew Weaver, Jamie Mills, Charles Wilson, Richard Adams, Anne Francis, Joanna Moschandreas, Pradeep S Virdee, Peter Dutton, Sharon Love, Val Gebski, Alastair Gray, Guy van Hazel, Ricky A Sharma
BACKGROUND: Data suggest selective internal radiotherapy (SIRT) in third-line or subsequent therapy for metastatic colorectal cancer has clinical benefit in patients with colorectal liver metastases with liver-dominant disease after chemotherapy. The FOXFIRE, SIRFLOX, and FOXFIRE-Global randomised studies evaluated the efficacy of combining first-line chemotherapy with SIRT using yttrium-90 resin microspheres in patients with metastatic colorectal cancer with liver metastases. The studies were designed for combined analysis of overall survival...
August 3, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28781170/haploidentical-donor-transplants-in-all
#12
Manjulika Das
No abstract text is available yet for this article.
August 3, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28760403/health-related-quality-of-life-for-immediate-versus-delayed-androgen-deprivation-therapy-in-patients-with-asymptomatic-non-curable-prostate-cancer-trog-03-06-and-vcog-pr-01-03-toad-a-randomised-multicentre-non-blinded-phase-3-trial
#13
Gillian M Duchesne, Henry H Woo, Madeleine King, Steven J Bowe, Martin R Stockler, Alice Ames, Catherine D'Este, Mark Frydenberg, Andrew Loblaw, Shawn Malone, Jeremy Millar, Keen Hun Tai, Sandra Turner
BACKGROUND: Androgen-deprivation therapy in patients with prostate cancer who have relapsed with rising prostate-specific antigen concentration only (PSA-only relapse), or with non-curable but asymptomatic disease at diagnosis, could adversely affect quality of life at a time when the disease itself does not. We aimed to compare the effect of immediate versus delayed androgen-deprivation therapy on health-related quality of life over 5 years in men enrolled in the TOAD (Timing of Androgen Deprivation) trial...
July 28, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28760402/androgen-deprivation-in-prostate-cancer-first-do-no-harm
#14
Fred Saad
No abstract text is available yet for this article.
July 28, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28760401/correction-to-lancet-oncol-2016-17-727-37
#15
(no author information available yet)
No abstract text is available yet for this article.
July 28, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28760400/new-perspectives-for-tas-102-task-successful
#16
Fotios Loupakis, Sara Lonardi
No abstract text is available yet for this article.
July 28, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28760399/tas-102-plus-bevacizumab-for-patients-with-metastatic-colorectal-cancer-refractory-to-standard-therapies-c-task-force-an-investigator-initiated-open-label-single-arm-multicentre-phase-1-2-study
#17
Yasutoshi Kuboki, Tomohiro Nishina, Eiji Shinozaki, Kentaro Yamazaki, Kohei Shitara, Wataru Okamoto, Takeshi Kajiwara, Toshihiko Matsumoto, Takahiro Tsushima, Nobuo Mochizuki, Shogo Nomura, Toshihiko Doi, Akihiro Sato, Atsushi Ohtsu, Takayuki Yoshino
BACKGROUND: In patients with heavily treated metastatic colorectal cancer, TAS-102-a combination of trifluridine and tipiracil-has shown a significant overall survival benefit compared with placebo. In preclinical models, TAS-102 plus bevacizumab has shown enhanced activity against colorectal cancer xenografts compared with that for either drug alone. In this phase 1/2 study, we assessed the activity and safety of TAS-102 plus bevacizumab. METHODS: We did this investigator-initiated, open-label, single-arm, multicentre, phase 1/2 trial of TAS-102 plus bevacizumab in four cancer centres in Japan...
July 28, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28757379/concurrent-chemotherapy-and-proton-beam-therapy-in-nsclc
#18
Manjulika Das
No abstract text is available yet for this article.
July 27, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28757378/the-true-value-of-altered-fractionation-in-head-and-neck-cancer
#19
Sandra Nuyts
No abstract text is available yet for this article.
July 27, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28757377/redefining-the-molecular-substructure-of-medulloblastoma
#20
Ramla Benmaamar
No abstract text is available yet for this article.
July 27, 2017: Lancet Oncology
journal
journal
20189
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"